For Funds

Scientific diligence for partners and principals at lean life-science funds.

We test the claims behind a seed or spinout deal — support, refute, and gaps — and return a citation-backed memo your IC or syndicate can actually use.

Most lean funds already expense external science help from the management company or deal OpEx — KOL conversations, IP screens, ad-hoc scientific review. BioticaBio is that line item with a structured method and a written, citation-backed deliverable.

When funds engage us

  • New inbound spinout / cold deck with strong narrative, weak claim structure
  • IC prep: support/refute read before partner meeting
  • Co-invest diligence: shared inspectable memo for the syndicate
  • Portfolio triage: which seed bets still hold under comparator failure?
  • LP / board pressure for a documented diligence process (not chat transcripts)

What you get

  • Make the claims explicit

    We decompose the thesis into the 5–8 claims your partners must believe to write the check.

  • Test them against evidence

    Independent literature, trials, patents, and comparator history — scored support / partial / refute, with gaps named.

  • Walk into IC with an artifact

    A human-reviewed, citation-backed memo and priority diligence questions — not a fluent AI essay or a call note.

Scope a diligence engagementSee how the method works →